US5001255A
(en)
*
|
1984-12-04 |
1991-03-19 |
Sandoz Pharm. Corp. |
Idene analogs of mevalonolactone and derivatives thereof
|
WO1987002662A2
(fr)
*
|
1985-10-25 |
1987-05-07 |
Sandoz Ag |
Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques
|
US4751235A
(en)
*
|
1986-12-23 |
1988-06-14 |
Sandoz Pharm. Corp. |
Anti-atherosclerotic indolizine derivatives
|
US5091378A
(en)
*
|
1987-05-22 |
1992-02-25 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
|
US4904691A
(en)
*
|
1987-12-21 |
1990-02-27 |
Rorer Pharmaceutical Corporation |
Novel HMG-CoA reductase inhibitors
|
US4822799A
(en)
*
|
1988-01-27 |
1989-04-18 |
Sandoz Pharm. Corp. |
Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
|
US4876280A
(en)
*
|
1988-03-10 |
1989-10-24 |
Sandoz Pharm. Corp. |
Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
|
US5506219A
(en)
*
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
EP0363934B1
(fr)
*
|
1988-10-13 |
1993-12-29 |
Sandoz Ag |
Procédé pour la préparation des acides hept-6-énoiques et heptanoiques substitués sur la position 7 et dérivés
|
FR2642065B1
(fr)
*
|
1989-01-24 |
1991-05-24 |
Lipha |
Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
|
US5025017A
(en)
*
|
1989-09-28 |
1991-06-18 |
E. R. Squibb & Sons, Inc. |
Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
|
US5189180A
(en)
*
|
1989-09-28 |
1993-02-23 |
E. R. Squibb & Sons, Inc. |
Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
|
JPH03173882A
(ja)
*
|
1989-09-29 |
1991-07-29 |
Tanabe Seiyaku Co Ltd |
クロメン又はチオクロメン誘導体、その製法及びその合成中間体
|
WO1992019239A1
(fr)
*
|
1991-05-01 |
1992-11-12 |
University Of New Mexico |
Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
|
WO1992019240A1
(fr)
*
|
1991-05-01 |
1992-11-12 |
University Of New Mexico |
Traitement d'aberrations cellulaires avec des biomodulateurs
|
US5256692A
(en)
*
|
1992-01-07 |
1993-10-26 |
E. R. Squibb & Sons, Inc. |
Sulfur-containing HMG-COA reductase inhibitors
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
US7276249B2
(en)
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US6774112B2
(en)
|
2001-04-11 |
2004-08-10 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
CA2463908A1
(fr)
|
2001-10-18 |
2003-04-24 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6806381B2
(en)
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
AU2002348276A1
(en)
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
AU2003225305A1
(en)
|
2002-05-08 |
2003-11-11 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
WO2003103632A1
(fr)
|
2002-06-10 |
2003-12-18 |
Elan Pharma International, Ltd. |
Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
|
ATE469645T1
(de)
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
DE60323536D1
(de)
|
2002-12-20 |
2008-10-23 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7829552B2
(en)
|
2003-11-19 |
2010-11-09 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyromimetics
|
CA2558766A1
(fr)
|
2004-03-05 |
2005-09-22 |
The Trustees Of The University Of Pennsylvania |
L'utilisation d'inhibiteurs mtp pour le traitement a faibles effets secondaires contre des affections liees a l'hyperlipidemie et l'hypercholesterolemie
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7368458B2
(en)
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076598A2
(fr)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Composes heterocycliques bicycliques en tant que modulateurs des recepteurs de canabinoides
|
US20060160850A1
(en)
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
EP2527337A1
(fr)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
AR056155A1
(es)
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
WO2007053819A2
(fr)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Inhibiteurs à base d'amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US8367112B2
(en)
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
EP2089355A2
(fr)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulateurs de recepteur de glucocorticoide, d'activite ap-1 et/ou nf- kappa b, et leur utilisation
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CN101820757A
(zh)
|
2007-06-01 |
2010-09-01 |
普林斯顿大学托管委员会 |
通过调节宿主细胞代谢途径治疗病毒感染
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
WO2009018065A2
(fr)
|
2007-07-27 |
2009-02-05 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de glucokinase et procédés pour les utiliser
|
AU2008302570B2
(en)
|
2007-09-20 |
2012-05-31 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
ES2448839T3
(es)
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
PE20091928A1
(es)
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
AU2010229653A1
(en)
|
2009-03-27 |
2011-10-20 |
Astrazeneca Ab |
Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
|
WO2011014520A2
(fr)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
|
JP2013507366A
(ja)
|
2009-10-09 |
2013-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Gpr119活性モジュレーターとしての化合物および組成物
|
US8871264B2
(en)
|
2009-11-13 |
2014-10-28 |
Astrazeneca Ab |
Immediate release tablet formulations
|
CA2780938A1
(fr)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Formulations de metformine a masse reduite
|
ES2689107T3
(es)
|
2009-11-13 |
2018-11-08 |
Astrazeneca Ab |
Formulaciones de tabletas bicapa
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
EP2558461B1
(fr)
|
2010-04-14 |
2015-12-02 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
|
CA2804926C
(fr)
|
2010-07-09 |
2019-01-08 |
James Trinca Green |
Systeme d'administration a liberation immediate/retardee en combinaison pour des medicaments a courte demi-vie comprenant de la remogliflozine
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2014052619A1
(fr)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
|
PT3489226T
(pt)
|
2012-11-20 |
2021-03-02 |
Lexicon Pharmaceuticals Inc |
Inibidores do cotransportador de sódio e glucose 1
|
AR094054A1
(es)
*
|
2012-12-19 |
2015-07-08 |
H Lundbeck As |
6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
TW201702271A
(zh)
|
2015-04-30 |
2017-01-16 |
哈佛大學校長及研究員協會 |
治療代謝病症之抗-ap2抗體及抗原結合劑
|
EA202190226A1
(ru)
|
2018-07-19 |
2021-06-16 |
Астразенека Аб |
СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
|
WO2020068661A1
(fr)
|
2018-09-26 |
2020-04-02 |
Lexicon Pharmaceuticals, Inc. |
Formes cristallines de n-(1 -((2-(diméthylamino)éthyl)amino)-2-m éthyl-1 -oopropan-2-yl)-4-(4-(2-méthyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(méthylthio)tétrahydro-2h-pyran-2-yl)benzyl) phényl)butanamide et procédés de synthèse associés
|
US11535600B2
(en)
|
2018-12-03 |
2022-12-27 |
H. Lundbeck A/S |
Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
|